Last checked at 29 Apr 2020 16:13
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Avacta Group Share News (AVCT)
AVCT Share
Price
AVCT Share
News
AVCT Share
Chat2
AVCT Share
Trades192
AVCT
Live RNS
AVCT Share
Charts
AVCT Level 2
Console
AVCT Live
Share Price
AVCT Broker
Ratings
AVCT Directors
Deals
AVCT Financial
Diary
AVCT
Fundamentals
AVCT Short
Positions1
AVCT
Media
Avacta Group Information
Share Price Information for Avacta Group (AVCT)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
45.00
Bid:
44.50
Ask:
45.50
Change:
-0.30 (-0.66%)
Spread:
1.00 (2.247%)
Open:
45.25
High:
45.25
Low:
44.25
Prev. Close:
45.30
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.22 Apr 2020 15:40
UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order
UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order
Read more22 Apr 2020 14:50
Avacta shares surge on progress with Covid test
(Sharecast News) - Avacta Group said on Wednesday that, in four weeks and "well ahead" of schedule, it had successfully generated multiple 'Affimer' reagents that bound the SARS-COV-2 viral antigen as part of the collaboration with Cytiva - formerly GE Healthcare Life Sciences - to develop an Affimer-based rapid test for the Covid-19 coronavirus infection.
Read more14 Apr 2020 16:06
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
Read more8 Apr 2020 10:41
Avacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes
Avacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes
Read more7 Apr 2020 07:31
Avacta Raises More-Than-Expected GBP3.8 Million In Share Placing
Avacta Raises More-Than-Expected GBP3.8 Million In Share Placing
Read more6 Apr 2020 12:42
Avacta raises ?3.75m, expects minimal impact from pandemic
(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that, in response to "substantial" institutional interest, it has conditionally raised gross proceeds of ?3.75m under a placing, through the issue of 20,833,333 new ordinary shares at a price of 18p each.
Read more2 Apr 2020 14:55
Avacta Announces GBP2 Million Subscription With Two Subscribers
Avacta Announces GBP2 Million Subscription With Two Subscribers
Read more3 Feb 2020 15:22
Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell
Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell
Read more3 Feb 2020 10:17
Avacta signs collaboration deal with Daewoong joint venture
(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced on Monday that it has signed a collaboration and license agreement with AffyXell Therapeutics - the recently-established joint venture with Daewoong Pharmaceutical - to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.
Read more28 Jan 2020 11:57
Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Read more23 Jan 2020 12:44
Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts
Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts
Read more23 Jan 2020 10:28
Avacta doubles revenues thanks to LG Chem milestone payment
(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.
Read more21 Jan 2020 12:48
Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director
Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director
Read more8 Jan 2020 15:27
Avacta Group enters joint venture with South Korea's Daewoong
(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.
Read more